Clinical and Translational Opportunities of Nanocarriers Containing RNAi for the Management of Triple‐Negative Breast Cancer

Author:

Sharma Saurabh1ORCID,Pradhan Rajesh2,Lee David1,Sharma Mahalaxmi3,Nasab Shima Zahed4,Hejmady Siddhanth5,Chander Subhash6,Mohaghegh Neda7,Maity Surjendu7,Khan Shahid8,Khademhosseini Ali7,Kirane Amanda1

Affiliation:

1. Department of Surgery Stanford School of Medicine Stanford University Medical Center Stanford CA 94305 USA

2. Department of Pharmacy Birla Institute of Technology and Science (BITS) Pilani 333031 India

3. Bakson Homoeopathic Medical College and Hospital Phase‐I Greater Noida Uttar Pradesh 201310 India

4. Department of Life Science Engineering Faculty of New Sciences and Technologies University of Tehran Tehran 143951561 Iran

5. Department of Pharmaceutical Sciences Experimental Therapeutics College of Pharmacy University of Iowa Iowa City IA 52242 USA

6. Amity Institute of Phytochemistry and Phytomedicine Amity University Uttar Pradesh Noida Uttar Pradesh 201313 India

7. Terasaki Institute for Biomedical Innovation Los Angeles CA 90064 USA

8. Department of Biomedical Engineering University of California Davis CA 95616 USA

Abstract

AbstractTriple‐negative breast cancer develops from malignant cells within the interior lining of milk ducts or, less frequently, in the stromal tissues and accounts for ≈15% of all breast cancers. Breast cancer is highly prevalent with the overall number of cases expected to reach 27.78 million by 2040, according to the World Health Organization. MiRNAs serve a novel role in management of breast cancer through their ability to indirectly control the translation of coding mRNA and regulate the expression of specific genes, which allows it to play a significant role in cancer therapeutics. However, inherent characteristics of miRNA including rapid clearance via renal excretion, degradation by nucleases in plasma, and additional factors limit its clinical application. To reduce these limitations, miRNA can be administered in conjunction small molecules with nanocarriers, which then allow it to impart its benefits including inhibition of epithelial–mesenchymal transitions, and inhibiting tumor angiogenesis. This review highlights the current application of nanocarrier‐based delivery approach of miRNA/siRNA for triple negative breast cancer treatment.

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3